ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Centre Léon Bérard at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Centre Léon Bérard takes part in 20 sessions at ESMO 2026 in Madrid. Its program spans emerging treatments and precision approaches in lung, gynaecological and rare cancers. Topics include genomic testing to diagnose complex sarcomas and registry data on uterine sarcoma characteristics and outcomes.

OrganizationESMO 2026 Attendance
Cancer centre & hospital
Comprehensive cancer centre in Lyon, France, part of the Unicancer network of French cancer centres.
Poster
Fri Oct 23
13:00–15:00
Chair
Fri Oct 23
16:15–17:45
Beyond traditional therapy: The impact of emerging approaches on sarcoma treatment
with University College London Hospitals
Sarcoma, CNS, head & neck and rare cancers
Chair
Sat Oct 24
10:15–11:45
ESMO-WHO-IARC collaboration in global cancer control
with International Agency for Research on Cancer (IARC)
Talk
Sat Oct 24
11:05–11:20
Systemic therapies: From localised to metastatic disease
Multidisciplinary insights for effective care in gynaecological sarcomas
Sarcoma, CNS, head & neck and rare cancers
Poster
Sat Oct 24
12:00–12:45
Causes of screen fail in recent early phase clinical trials in oncology
Saturday Poster Display session 6
Satellite
Sat Oct 24
13:15–13:20
Audience polling
GSK - From Discovery to Impact: ADCs in Endometrial and Ovarian Cancer Care · with Hospital Universitario Puerta de Hierro Majadahonda, University of California San Diego
Gynaecological cancers
Satellite
Sat Oct 24
13:55–14:10
Spotlight on PROC: An In-Depth Exploration of ADCs in Development
GSK - From Discovery to Impact: ADCs in Endometrial and Ovarian Cancer Care
Gynaecological cancers
Chair
Sun Oct 25
08:30–09:15
Locally advanced vulvar cancer
Gynaecological cancers
Chair
Sun Oct 25
08:30–10:00
Rapid oral 2: NSCLC, metastatic
with Hospital Universitario 12 de Octubre, Gustave Roussy
Lung & thoracic cancers
Abstract
Sun Oct 25
09:02–09:14
Invited Discussant 2661RO and 2617RO
Rapid oral 2: NSCLC, metastatic
Lung & thoracic cancers
Chair
Sun Oct 25
10:15–11:45
Proffered paper: Policy
with Netherlands Cancer Institute
Abstract
Sun Oct 25
10:35–10:45
Invited Discussant 3312O and 3313O
Proffered paper: Policy
Abstract
Mon Oct 26
09:07–09:12
Abstract
Mon Oct 26
09:24–09:29
Chair
Mon Oct 26
10:15–11:30
Optimal management of high-grade serous ovarian cancer with BRCA mutation
with LMU University Hospital Munich
Gynaecological cancers
Talk
Mon Oct 26
10:45–11:00
Drug interventions to reduce the risk of second primaries: Where do we stand?
Addressing the risk of second primary cancers
Nursing & supportive care
Poster
Mon Oct 26
12:00–12:45
Added value of systematic sequencing in diagnostic of complex genomic sarcoma: Results of the prospective RNASarc study
Monday Poster Display session 6
Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Poster
Mon Oct 26
12:00–12:45
Genomic landscape of head and neck squamous cell carcinoma in a prospective molecular screening program: The PROFILER experience
Monday Poster Display session 2
Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Poster
Mon Oct 26
12:00–12:45
Uterine sarcomas: Heterogeneity of presentation and outcome for the 3,110 patients from the NETSARC+ registry
Monday Poster Display session 6
Gynaecological cancersSarcoma, CNS, head & neck and rare cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Centre Léon Bérard

Tell us what you sell and we’ll find the people at Centre Léon Bérard most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction